AcquiredStartups
Home/North America/Healthtech & bio
Acquisition · Healthtech & bio · United States

argenx agrees to buy Unnatural Products for $550 million upfront to add oral peptide drug discovery

The two companies had worked together for more than two years, and argenx already owned part of the Santa Cruz biotech. The full price could reach about $1.15 billion if development and regulatory milestones are met.

ASAcquired deals deskNorth America9 November 2026 · 3 min read
argenx acquires Unnatural Products
Photo: Goldmund100 / Wikimedia Commons, CC BY-SA 3.0

argenx, the immunology drug company listed on Euronext and Nasdaq, has agreed to acquire Unnatural Products (UNP), a privately held biotech in Santa Cruz, California, that designs macrocyclic peptide drugs with the help of machine learning. The deal was announced on November 9, 2026, and both companies' boards have approved it.

argenx will pay $550 million upfront in cash, funded from cash on hand, for the UNP shares it does not already own. It will pay up to $595 million more if specified development and regulatory milestones are met, through contingent value rights, which puts the total potential value at about $1.15 billion. The deal is expected to close by the end of 2026, subject to customary conditions.

UNP will keep operating from its Santa Cruz site and its team and leadership will stay in place. The site will become argenx's centre for discovering macrocyclic peptides.

What Unnatural Products built

UNP works on macrocyclic peptides, ring-shaped molecules it is developing as drugs that patients could take by mouth. Its aim is to reach high-value targets that have been hard or impossible to drug, including targets inside cells. The company's founders came out of academic research into how the macrocycles found in nature work.

Over roughly ten years the company built a discovery platform that combines AI-guided molecule design, the synthesis of very large numbers of compounds in parallel, and screening directly in biological assays. argenx said the approach uses parallel experiments and machine learning to address problems in medicinal chemistry that have held macrocycles back.

UNP has more than 50 employees. In under five years it signed four partnerships with large drug companies: Novartis, Merck, BridgeBio and argenx itself. Droia Ventures reported that the Novartis deal carried up to $100 million in upfront and near-term milestone payments.

“UNP adds macrocyclic peptide capabilities that are highly complementary to our antibody engineering and creates new possibilities for oral and long-acting medicines.”Karen Massey, Chief Executive Officer, argenx
Funding historyTotal raised $77m
2023Series AMerck Global Health Innovation Fund, ARTIS Ventures$32m
2026Series BThe Venture Collective$45m

Why argenx is buying

argenx's existing pipeline is built on antibody engineering. It said UNP's macrocycles complement that work, give it a path to oral and longer-acting medicines and open up targets that are hard to drug. Karen Massey, argenx's chief executive, said the company wants to be the leading innovator in immunology and is investing with discipline where it matters most for patients.

The deal grows out of an existing relationship. argenx said the companies have worked together for more than two years; AcquisitionsNews dates their multi-target research collaboration, which came with an equity investment by argenx, to July 2025. argenx also took part in UNP's Series B round in March 2026. Massey said the partnership had shown the companies shared a way of working that puts science first, is entrepreneurial and is focused on patients, and that argenx wants to keep what made UNP successful.

After closing, UNP will lead discovery work under a strategy agreed with argenx, and argenx will handle clinical development and commercialisation of any resulting drugs. Morgan Stanley was argenx's exclusive financial adviser and DLA Piper its legal adviser. Latham & Watkins advised UNP.

The founders and the funding

Cameron Pye, UNP's chief executive, and Joshua Schwochert, its chief scientific officer, founded the company in 2016 in the final year of their doctoral research in Scott Lokey's lab at the University of California, Santa Cruz. They started it in Schwochert's garage.

In December 2023 UNP raised a $32 million Series A co-led by Merck Global Health Innovation Fund and ARTIS Ventures, with First Spark Ventures, The Venture Collective, Humain Ventures, LongeVC and Not Boring Capital joining as new investors. Other investors named in the company's description include Abstract Ventures, Asset Management Ventures, Better Ventures, Blue Bear Ventures, Rising Tide Fund and Gaingels.

In March 2026 it raised a $45 million Series B led by The Venture Collective, with argenx, Droia Ventures, Merck GHIF, ARTIS Ventures and First Spark Ventures taking part. Those two rounds total $77 million. Pye said argenx offered the right setting to speed up the company's plans, and Schwochert said UNP had looked at several ways to grow before choosing argenx because of its belief in the science, its cultural fit and its promise to preserve the company's inventive spirit.

What it means for partners and staff

UNP's partner list shows that several large drugmakers wanted access to its platform before argenx moved to buy it outright. The announcement did not say whether the Novartis, Merck and BridgeBio collaborations will continue unchanged under argenx ownership.

For staff, the main commitment is continuity: the team stays in Santa Cruz, and Schwochert said the company was glad to stay true to its roots there. argenx did not say how many people it expects to add to the site or how much it plans to spend on it after closing.

Sources